377 related articles for article (PubMed ID: 25902879)
1. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.
Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J
Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
3. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.
van Veldhuisen DJ; Linssen GC; Jaarsma T; van Gilst WH; Hoes AW; Tijssen JG; Paulus WJ; Voors AA; Hillege HL
J Am Coll Cardiol; 2013 Apr; 61(14):1498-506. PubMed ID: 23500300
[TBL] [Abstract][Full Text] [Related]
4. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.
Meijers WC; Januzzi JL; deFilippi C; Adourian AS; Shah SJ; van Veldhuisen DJ; de Boer RA
Am Heart J; 2014 Jun; 167(6):853-60.e4. PubMed ID: 24890535
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
[TBL] [Abstract][Full Text] [Related]
8. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.
Palazzuoli A; Ruocco G; Beltrami M; Nuti R; Cleland JG
Clin Res Cardiol; 2018 Jul; 107(7):586-596. PubMed ID: 29532155
[TBL] [Abstract][Full Text] [Related]
9. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
10. Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study.
Boldanova T; Noveanu M; Breidthardt T; Potocki M; Reichlin T; Taegtmeyer A; Christ M; Laule K; Stelzig C; Mueller C
Int J Cardiol; 2010 Jul; 142(3):265-72. PubMed ID: 19185372
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction.
Polat V; Bozcali E; Uygun T; Opan S; Karakaya O
Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041
[TBL] [Abstract][Full Text] [Related]
12. Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients.
Feola M; Testa M; Leto L; Cardone M; Sola M; Rosso GL
Medicine (Baltimore); 2016 Jun; 95(26):e4014. PubMed ID: 27368017
[TBL] [Abstract][Full Text] [Related]
13. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
[TBL] [Abstract][Full Text] [Related]
14. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction.
Kato N; Kinugawa K; Shiga T; Hatano M; Takeda N; Imai Y; Watanabe M; Yao A; Hirata Y; Kazuma K; Nagai R
J Cardiol; 2012 Jul; 60(1):23-30. PubMed ID: 22445598
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
[TBL] [Abstract][Full Text] [Related]
16. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
17. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
[TBL] [Abstract][Full Text] [Related]
18. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
19. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
